Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102371 | 0.84 | MGLL (0.52) | LTA4HPTGS1TRPV1EPHX2MGLL | |
| SCHEMBL102685 | 0.82 | MGLL (0.58) | LTA4HPTGS1TRPV1EPHX2MGLL | |
| SCHEMBL101957 | 0.82 | MGLL (0.58) | LTA4HPTGS1TRPV1EPHX2MGLL | |
| SCHEMBL102356 | 0.82 | MGLL (0.58) | LTA4HPTGS1TRPV1EPHX2MGLL | |
| SCHEMBL101952 | 0.82 | MGLL (0.58) | LTA4HPTGS1TRPV1EPHX2MGLL | |
| SCHEMBL102358 | 0.82 | MGLL (0.58) | LTA4HPTGS1TRPV1EPHX2MGLL | |
| SCHEMBL102366 | 0.81 | PTGS1 (0.54) | LTA4HPTGS1TRPV1EPHX2TSHR | |
| SCHEMBL136890 | 0.78 | PTGS1 (0.46) | LTA4HTP53MAPTPTGS1TSHR | |
| SCHEMBL101661 | 0.76 | PTGS1 (0.49) | LTA4HPTGS1TRPV1TSHRGLA | |
| SCHEMBL102357 | 0.76 | PTGS1 (0.51) | TP53PTGS1TRPV1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | claimed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | claimed |
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | disclosed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | disclosed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | FAAH, FAAH2, TRPV1 | LTA4H 16/4885TP53 3302/4885MAPT 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.